Oxford BioMedica PLC
LSE:OXB

Watchlist Manager
Oxford BioMedica PLC Logo
Oxford BioMedica PLC
LSE:OXB
Watchlist
Price: 619 GBX Market Closed
Market Cap: 745.9m GBX

Intrinsic Value

The intrinsic value of one OXB stock under the Base Case scenario is 543.1 GBX. Compared to the current market price of 619 GBX, Oxford BioMedica PLC is Overvalued by 12%.

The Intrinsic Value is calculated as the average of DCF and Relative values:

OXB Intrinsic Value
543.1 GBX
Overvaluation 12%
Intrinsic Value
Price
Base Case Scenario

Valuation History
Oxford BioMedica PLC

What is Valuation History?
Ask AI Assistant
What other research platforms think about OXB?

Let our AI compare Alpha Spread’s intrinsic value with external valuations from Simply Wall St, GuruFocus, ValueInvesting.io, Seeking Alpha, and others.

Discover External Valuations
Why is OXB valued this way?

Let our AI break down the key assumptions behind the intrinsic value calculation for Oxford BioMedica PLC.

Explain Valuation
Compare OXB to

Fundamental Analysis

Company Overview
Loading...
Economic Moat
Loading...
Earnings Call
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about OXB?
Bearish
Neutral
Bullish
Financials
Annual
Quarterly
TTM
Annual
Quarterly
TTM

Balance Sheet Decomposition
Oxford BioMedica PLC

Current Assets 131.8m
Cash & Short-Term Investments 53.9m
Receivables 57.1m
Other Current Assets 20.8m
Non-Current Assets 84.5m
PP&E 55.3m
Intangibles 24.3m
Other Non-Current Assets 4.9m
Current Liabilities 69.7m
Accounts Payable 10m
Accrued Liabilities 12.2m
Other Current Liabilities 47.4m
Non-Current Liabilities 113.9m
Long-Term Debt 100.8m
Other Non-Current Liabilities 13.1m
Efficiency

Free Cash Flow Analysis
Oxford BioMedica PLC

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
Oxford BioMedica PLC

Revenue
151.2m GBP
Cost of Revenue
-84.5m GBP
Gross Profit
66.7m GBP
Operating Expenses
-97.4m GBP
Operating Income
-30.7m GBP
Other Expenses
-6.4m GBP
Net Income
-37.1m GBP
Fundamental Scores

OXB Profitability Score
Profitability Due Diligence

Oxford BioMedica PLC's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

Healthy Gross Margin
Sustainable 3Y Average Gross Margin
Declining Net Margin
Declining Operating Margin
16/100
Profitability
Score

Oxford BioMedica PLC's profitability score is 16/100. The higher the profitability score, the more profitable the company is.

OXB Solvency Score
Solvency Due Diligence

Oxford BioMedica PLC's solvency score is 26/100. The higher the solvency score, the more solvent the company is.

Short-Term Solvency
Long-Term Solvency
Positive Net Debt
High D/E
26/100
Solvency
Score

Oxford BioMedica PLC's solvency score is 26/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

OXB Price Targets Summary
Oxford BioMedica PLC

Wall Street analysts forecast OXB stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for OXB is 748.85 GBX with a low forecast of 455.51 GBX and a high forecast of 1 018.5 GBX.

Lowest
Price Target
455.51 GBX
26% Downside
Average
Price Target
748.85 GBX
21% Upside
Highest
Price Target
1 018.5 GBX
65% Upside
View Analyst Estimates
View Analyst Estimates

Dividends

Oxford BioMedica PLC
does not pay dividends
Shareholder Yield

Current shareholder yield for OXB is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
No dividends
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y

OXB News

Other Videos
What is the Intrinsic Value of one OXB stock?

The intrinsic value of one OXB stock under the Base Case scenario is 543.1 GBX.

Is OXB stock undervalued or overvalued?

Compared to the current market price of 619 GBX, Oxford BioMedica PLC is Overvalued by 12%.

Back to Top